Gujarat Themis Biosyn Limited (NSE:GUJTHEM)

Market Cap	40.52B
Revenue (ttm)	1.48B
Net Income (ttm)	445.97M
Shares Out	n/a
EPS (ttm)	4.10
PE Ratio	90.86
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,245
Average Volume	24,115
Open	365.75
Previous Close	367.70
Day's Range	364.60 - 389.70
52-Week Range	192.35 - 501.00
Beta	-0.49
RSI	55.67
Earnings Date	Aug 11, 2025

About Gujarat Themis Biosyn

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis; Rifamycin-O; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 159
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GUJTHEM

Financial Performance

In 2024, Gujarat Themis Biosyn's revenue was 1.51 billion, a decrease of -11.20% compared to the previous year's 1.70 billion. Earnings were 487.72 million, a decrease of -17.56%.